title: Treatment of benign prostatic hyperplasia through transurethral needle ablation (TUNA). Review of the literature and six years of clinical experience.
abstract: Following FDA clearance and the establishment of Medicare coverage, transurethral needle ablation (TUNA) has become an established and widely-adopted treatment method for BPH in the USA. Germany is lagging behind at present, though a change can also be recognized there. The lack of long-term data has often been criticized. This review presents an overview of clinical outcomes of TUNA, long-term results and patient selection criteria.
authors.affiliation: Department of Urology, University of Cologne, Cologne, Germany. Moritz.Braun@medizin.uni.koeln.de
authors.forename: M
authors.initials: M
authors.lastname: Braun
authors.forename: M
authors.initials: M
authors.lastname: Mathers
authors.forename: B
authors.initials: B
authors.lastname: Bondarenko
authors.forename: U
authors.initials: U
authors.lastname: Engelmann
mesh_terms: D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000150:complications / Q000503:physiopathology / Q000601:surgery*; D013997:Time Factors; D020728:Transurethral Resection of Prostate; D016055:Urinary Retention / Q000150:complications; D014563:Urodynamics